
GLP-1 Non-Responders: Scientists Probe Hormonal and Genetic Drivers of Variable Weight Loss
While GLP-1 medications like semaglutide and tirzepatide help many patients lose significant weight, 10–15% of users experience minimal or no results. Researchers are investigating why this occurs, with early evidence pointing to biological sex, oestrogen levels, and genetic factors as key drivers of individual response. The Endocrine Society has designated understanding this heterogeneity as a priority to enable personalized treatments.







